10:58 11/02 UTC — Mixed
U.S. stock futures are attempting a morning bounce supported by lower crude oil prices, though broader technical indicators signal underlying market weakness as NDX enters a bearish mode. Biotech stocks are displaying sharp divergence following INO's FDA accelerated approval for VOCERYQ, which is exerting heavy competitive pressure on rival PGEN. Meanwhile, major technology tickers continue to face trader scrutiny regarding massive AI capital expenditures.
U.S. stock futures are attempting a morning recovery supported by falling crude oil prices, attempting to rebound from recent weekly losses. However, underlying sentiment remains cautious as technical indicators highlight a bearish trend signal on NDX after weeks of gains. Investors are increasingly questioning mega-cap AI capital expenditure profitability, creating persistent cross-currents across broader equities.
Outlook
Mixed · Intraday (Medium)
Base — Likely
Indices trade in a tight range as morning futures gains face resistance at key technical reversal levels amid tech sector hesitation.
Bull — Possible
Softening oil prices and pre-market short squeezing propel SPY above key technical resistance zones.
Bear — Possible
AI capex fatigue and continued selling in mega-cap tech push major market indices below key morning support levels.
Hot tickers
- INTC Bearish — Sustained heavy selling sentiment following severe market drop, alongside criticisms of substrate execution and competitive market share loss.
- INO Bullish — FDA accelerated approval for VOCERYQ as the first DNA medicine in the US for RRP.
- PGEN Bearish — Facing heavy selling pressure due to competitive threat following FDA approval of rival INO's drug.
- IONQ Neutral — Traders debate dilution from capital raises and acquisition against long-term quantum commercialization prospects.
- NVDA Bullish — Holding above its 200-day moving average keeps the broader bullish technical trend intact for traders.
Themes
- Tech & AI Capex Sustainability Concerns
- Biotech Regulatory Approvals & Competitive Repricing
- Macro Relief from Falling Oil Prices
Risks
- Nasdaq-100 technical reversal signal into bearish territory
- Share dilution risks from capital raises in mid-cap tech
- Persistent divergence between equal-weighted and market-cap weighted index performance
Get digest by email Open live dashboard All digests About FC Global